Welcome To PPIKB

PPIDT00026

Drug Information

Name	Human immunoglobulin G
Sequence	PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKLSSVTAADTAVYYCARVPLVVNPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPQPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
DrugBank_ID	DB00028
Type	biotech
Indication	Human immunoglobulin G is indicated for the following conditions: ### Primary Immunodeficiency - for the treatment of primary immunodeficiency in adult and pediatric patients[L39920, L39930, L39935, L39940, L39945, L39950, L39955, L39960, L39965, L39975, L39980, L40029, L40034, L40044] - in combination with [hyaluronidase (human recombinant)] for the treatment of primary immunodeficiency in patients ≥2 years of age.[L42760] ### Immune Thrombocytopenic Purpura (ITP) - for the treatment of acute or chronic immune thrombocytopenic purpura in adult and pediatric patients[L39940, L39950, L39960, L39965, L39970, L39975, L39980] ### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - for the treatment of CIDP in adult patients[L39955, L39965, L39975, L39980, L40034] - in combination with hyaluronidase (human recombinant) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)[L40039] ### Multifocal Motor Neuropathy (MMN) - for maintenance therapy to improve muscle strength and disability in adult patients with MMN[L39955] ### Prophylaxis of Bacterial Infection - for the prevention of bacterial infections in patients with hypogammaglobulinemia and/or B-cell chronic lymphocytic leukemia[L39960] ### Coronary Artery Aneurysm Associated With Kawasaki Syndrome - for the prevention of coronary artery aneurysms in pediatric patients with Kawasaki syndrome[L39960] ### Dermatomyositis - for the treatment of dermatomyositis in adult patients[L39970]

Dosage Forms

Form	Route	Strength
Liquid	Intravenous	100 mg/1mL
Liquid	Intravenous	5 g/50mL
Injection, solution	Intramuscular; Subcutaneous
Solution	Intramuscular; Subcutaneous	800 mg
Solution	Intramuscular; Subcutaneous	80000000 mg
Solution	Intramuscular; Subcutaneous	320 mg
Solution	Intramuscular; Subcutaneous	32000000 mg
Injection, solution	Intravenous	1 g/10mL
Injection, solution	Intravenous	10 g/100mL
Injection, solution	Intravenous	5 g/50mL
Injection, powder, lyophilized, for solution	Intravenous	12 g/1
Injection, powder, lyophilized, for solution	Intravenous	3 g/1
Injection, powder, lyophilized, for solution	Intravenous	6 g/1
Solution	Intravenous	1000000 g
Solution	Subcutaneous	1 g / 6 mL
Solution	Subcutaneous	1.65 g / 10 mL
Solution	Subcutaneous	165 mg/1mL
Solution	Subcutaneous	2 g / 12 mL
Solution	Subcutaneous	3.3 g / 20 mL
Solution	Subcutaneous	4 g / 24 mL
Solution	Subcutaneous	8 g / 48 mL
Injection, solution	Parenteral
Injection, solution	Subcutaneous	200 mg/1mL
Injection, solution	Subcutaneous
Solution	Subcutaneous	20000000 mg
Solution	Parenteral
Injection, solution	Intravenous	0.5 g/10mL
Injection	Intravenous	0.05
Solution, concentrate	Intravenous	1000000 g
Solution, concentrate	Intravenous	20 g
Solution, concentrate	Intravenous	2000000 g
Solution	Intravenous	0.05
Solution, concentrate	Intravenous	0.5 g
Solution, concentrate	Intravenous	10 g
Solution	Intravenous	2.5 g
Solution	Intravenous	20 g
Injection, solution	Intravenous	0.05 g/1mL
Injection, solution	Intravenous	50 MG/ML
Solution	Intravenous	100 mg/ml
Injection, solution	Intramuscular	0.165 g/1mL
Liquid	Intramuscular	0.165
Injection	—	1.65 g
Solution	Intramuscular	0.18
Solution	Intravenous	50 mg / mL
Powder, for solution	Intravenous	50 MG/ML
Injection, solution	Intravenous; Subcutaneous	100 mg/1mL
Injection, powder, lyophilized, for solution; kit	Intravenous	50 mg/1mL
Kit	Intravenous	50 mg/1mL
Kit; powder, for solution; solution	Intravenous	10 g / vial
Kit; powder, for solution; solution	Intravenous	5 g / vial
Powder, for solution	Intravenous	2.5 g / vial
Powder, for solution	Intravenous	0.5 g / vial
Injection, powder, for solution	Intravenous	52 mg/ml
Injection, powder, for solution	Intravenous
Injection	Intravenous; Subcutaneous	10 g/100mL
Solution	Subcutaneous	16500000 mg
Solution	Intravenous	5 g/50mL
Solution	Intravenous	5 g/100mL
Liquid	Intramuscular	165 mg / mL
Injection, solution	Intravascular	50 mg/1ml
Injection	Intravenous	1 g/1g
Solution	Intravenous; Subcutaneous	10 g / 100 mL
Injection	Intravenous	0.1 g/ml
Injection, solution	Intravenous	10 g
Injection, solution	Intravenous	20 g
Injection, solution	Intravenous	5 g
Injection, solution	Intravenous; Subcutaneous	0.1
Injection, solution	Intravenous; Subcutaneous	0.1 g/mL
Injection, solution	Intravenous	5 g/100ml
Injection, solution	Subcutaneous	200 MG/ML
Liquid	Subcutaneous	0.2 g/1mL
Solution	Subcutaneous	200 mg / mL
Solution	Subcutaneous	4 g
Injection, solution	Subcutaneous	200 g/L
Solution	Subcutaneous	1 g
Solution	Subcutaneous	100000 g
Solution	Subcutaneous	2 g
Solution	Subcutaneous	200000 g
Solution	Subcutaneous	400000 g
Injection, solution	Subcutaneous	100 MG/ML
Kit; solution	Subcutaneous
Solution	Subcutaneous
Injection	—	100 mg/mL
Solution	Subcutaneous	10000000 mg
Injection, solution	Intravenous	2.5 G
Solution	Intravenous	100000 g
Solution	Intravenous	10 gr/200ml
Injection, solution	Intravenous	1 g/20ml
Solution	Intravenous	5000000 mg
Injection, solution	Intravenous	2.5 g/50ml
Solution	Intravenous	5 gr/100ml
Solution	Intravenous	50 mg/ml
Solution	Intravenous	50 mg (titer)
Solution	Intravenous	5000000 mg (titer)
Liquid	Intravenous	50 mg / mL
Solution	Intravenous	10 g / 100 mL
Solution	Intravenous	5 g / 100 mL
Solution	Parenteral	16000000 mg
Solution, concentrate	Intravenous	5000000 mg
Injection	Intravenous	6 g/100mL
Injection, solution	Intravenous	100 G/L
Injection, solution	Intravenous	50 G/L
Solution	Intravenous	500000 g
Injection, solution	Intravenous	10 g/200ml
Injection, solution	Intravenous	20 g/200ml
Injection, solution	Intravascular	100 MG/ML
Injection, solution	Intravenous	100 MG/ML
Kit; liquid; powder, for solution	Intravenous
Aerosol, spray	Nasal
Aerosol, spray	Nasal	0.15 g/100mL
Injection, solution	Parenteral	160 MG/ML
Injection, solution	Intravenous
Solution	Intravenous; Subcutaneous	10000000 mg
Injection, solution	Intravenous; Subcutaneous	10 gr/100ml
Injection, solution	Intravenous; Subcutaneous	2.5 gr/25ml
Injection, solution	Intravenous	20 gr/200ml
Injection, solution	Intravenous	30 gr/300ml
Injection, solution	Intravenous; Subcutaneous	5 gr/50ml
Injection, solution	Subcutaneous	160 MG/ML
Injection, solution	Intravenous	0.05
Solution	Intravenous	100 mg / mL
Solution	Intravenous	10000000 mg
Solution	Intravenous
Solution	Intravenous	50 mg/1mL
Solution	Intravenous	100000000 mg
Injection, solution	Intramuscular; Subcutaneous	165 MG/ML
Injection, powder, for solution	Parenteral	70 mg/ml
Solution	Intravenous	100 mg/1mL
Injection	Intramuscular	160 mg/ml
Solution	Intravascular	50 mg/1ml
Injection	Intravenous	50 mg/ml
Liquid	Intravenous	10 g/100mL
Liquid	Intravenous	20 g/200mL
Liquid	Intravenous	40 g/400mL
Solution	Intravenous	0.1
Injection	Parenteral	10 g/100ml
Solution	Intravenous	10 g
Solution	Intravenous	2000000 g
Solution	Intravenous	5 g
Injection	Parenteral
Injection	Parenteral	5 g/50ml
Solution	Intravenous	100 g/L
Solution	Intravenous	250000 g
Injection, solution	Subcutaneous	300 mg/300mg
Solution	Intravenous	120 g / L
Injection, solution	Intramuscular; Subcutaneous	160 MG/ML
Injection, powder, for solution	Intravenous	250000 g
Injection, powder, lyophilized, for solution	Intravenous	10 g/200ml
Injection, powder, lyophilized, for solution	Intravenous	5 g/100ml
Injection, powder, lyophilized, for solution	Intravenous	500000 g
Injection, solution	Intravenous	50 mg/1ml
Injection, solution	—	160 MG/ML
Solution	Subcutaneous	160 mg / mL
Solution	Subcutaneous	160 mg/1mL
Liquid	Intramuscular; Intravenous	1500 [iU]/1mL
Liquid	Intramuscular; Intravenous	15000 [iU]/1mL
Liquid	Intramuscular; Intravenous	2500 [iU]/1mL
Liquid	Intramuscular; Intravenous	5000 [iU]/1mL
Liquid	Intramuscular; Intravenous	600 [iU]/1mL
Solution	Subcutaneous	0.2
Solution	Subcutaneous	200 mg/1mL
Injection, solution	Intravascular	20 g/100ml

Target Information

Role	Uniprot_ID	Gene_Name	Entity_Name	Organism	Actions	Internal link
target	P12314	FCGR1A	High affinity immunoglobulin gamma Fc receptor I	Homo sapiens	antagonist	Link
target	Q92637	FCGR1BP	Putative high affinity immunoglobulin gamma Fc receptor IB	Homo sapiens	antagonist	Link
target	P12318	FCGR2A	Low affinity immunoglobulin gamma Fc region receptor II-a	Homo sapiens	antagonist	Link
target	P31994	FCGR2B	Low affinity immunoglobulin gamma Fc region receptor II-b	Homo sapiens	antagonist	Link
target	P31995	FCGR2C	Low affinity immunoglobulin gamma Fc region receptor II-c	Homo sapiens	antagonist	Link
target	P08637	FCGR3A	Low affinity immunoglobulin gamma Fc region receptor III-A	Homo sapiens	antagonist	Link
target	O75015	FCGR3B	Low affinity immunoglobulin gamma Fc region receptor III-B	Homo sapiens	antagonist	Link
target	P01024	C3	Complement C3	Homo sapiens	binder	Link
target	P0C0L4	C4A	Complement C4-A	Homo sapiens	binder	Link
target	P0C0L5	C4B	Complement C4-B	Homo sapiens	binder	Link
target	P01031	C5	Complement C5	Homo sapiens	binder	Link